Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 12/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30850478 | 1.00 | ADORA2A (0.48) | ADORA2AADORA3ADORA1ADORA2BKCNA5 | |
| SCHEMBL29762087 | 0.93 | ADORA3 (0.55) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL26628409 | 0.93 | ADORA3 (0.55) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL26628462 | 0.93 | ADORA3 (0.55) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL29073776 | 0.93 | ADORA3 (0.55) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL24600929 | 0.93 | ADORA3 (0.55) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL29073777 | 0.93 | ADORA3 (0.55) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL30850619 | 0.93 | ADORA3 (0.55) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL30850626 | 0.92 | ADORA3 (0.46) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL26628587 | 0.92 | ADORA3 (0.46) | ADORA2AADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116975-A1 | ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2024-04-11 | — | — | US | disclosed |
| EP-4273153-A1 | ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF | Zhejiang Vimgreen Pharmaceuticals, Ltd (CN) | 2023-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116975-A1 | ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF | ADORA3, ADORA2A, ADORA2B | ADORA2A 2/4885ADORA3 1/4885ADORA1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.